What is the stock price of BLACKROCK HEALTH SCIENCES today?

The current stock price of BME is 36.66 USD . The price increased by 0.05% in the last trading session.

What is the ticker symbol for BLACKROCK HEALTH SCIENCES stock?

The exchange symbol of BLACKROCK HEALTH SCIENCES is BME and it is listed on the New York Stock Exchange, Inc. exchange.

On which exchange is BME stock listed?

BME stock is listed on the New York Stock Exchange, Inc. exchange.

BME Stock Price - BLACKROCK HEALTH SCIENCES Stock Price, News and Overview

Fundamental Rating

Taking everything into account, BME scores 2 out of 10 in our fundamental rating. BME was compared to 0 industry peers in the Unkown industry. BME may be in some trouble as it scores bad on both profitability and health. BME is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year BME was profitable.

In the past year BME had a positive cash flow from operations.

Of the past 5 years BME 4 years were profitable.

The reported operating cash flow has been mixed in the past 5 years: BME reported negative operating cash flow in multiple years.

1.2 Ratios

		Industry Rank	Sector Rank
ROA	4.36%
ROE	4.4%
ROIC	0.13%

ROA(3y)1.06%

ROA(5y)5.33%

ROE(3y)1.07%

ROE(5y)5.44%

ROIC(3y)0.2%

ROIC(5y)0.12%

1.3 Margins

In the last couple of years the Profit Margin of BME has declined.

In the last couple of years the Operating Margin of BME has remained more or less at the same level.

		Industry Rank	Sector Rank
OM	12.29%
PM (TTM)	317.04%
GM	100%

OM growth 3Y169.88%

OM growth 5Y-0.74%

PM growth 3Y-30.97%

PM growth 5Y-28.42%

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BME has less shares outstanding than it did 1 year ago.

Compared to 5 years ago, BME has more shares outstanding

BME has a worse debt/assets ratio than last year.

2.2 Solvency

BME has an Altman-Z score of 67.46. This indicates that BME is financially healthy and has little risk of bankruptcy at the moment.

The Debt to FCF ratio of BME is 0.00, which is an excellent value as it means it would take BME, only 0.00 years of fcf income to pay off all of its debts.

BME has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.

Although BME does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	67.46

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 0.29 indicates that BME may have some problems paying its short term obligations.

A Quick Ratio of 0.29 indicates that BME may have some problems paying its short term obligations.

		Industry Rank	Sector Rank
Current Ratio	0.29
Quick Ratio	0.29

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

BME shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.59%, which is quite good.

Measured over the past years, BME shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -24.80% on average per year.

BME shows a decrease in Revenue. In the last year, the revenue decreased by -7.64%.

BME shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.91% yearly.

EPS 1Y (TTM)12.59%

EPS 3Y-26.89%

EPS 5Y-24.8%

EPS Q2Q%-372.58%

Revenue 1Y (TTM)-7.64%

Revenue growth 3Y5.76%

Revenue growth 5Y8.91%

Sales Q2Q%-10.82%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 22.77 indicates a rather expensive valuation of BME.

When comparing the Price/Earnings ratio of BME to the average of the S&P500 Index (27.45), we can say BME is valued inline with the index average.

		Industry Rank	Sector Rank
PE	22.77
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	7.18
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BME has a Yearly Dividend Yield of 8.01%, which is a nice return.

BME's Dividend Yield is rather good when compared to the S&P500 average which is at 2.42.

		Industry Rank	Sector Rank
Dividend Yield	8.01%

5.2 History

The dividend of BME has a limited annual growth rate of 3.39%.

BME has been paying a dividend for at least 10 years, so it has a reliable track record.

BME has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.

Dividend Growth(5Y)3.39%

Div Incr Years1

Div Non Decr Years10

5.3 Sustainability

BME pays out 150.00% of its income as dividend. This is not a sustainable payout ratio.

BME's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.

DP150%

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BLACKROCK HEALTH SCIENCES

NYSE:BME (7/3/2025, 7:05:20 PM)

After market: 36.66 0 (0%)

36.66

+0.02 (+0.05%)

Chartmill FA Rating

GICS SectorN/A

GICS IndustryGroupN/A

GICS IndustryN/A

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners21.79%

Inst Owner Change-11.54%

Ins Owners0%

Ins Owner Change0%

Market Cap473.65M

Analysts0

Price TargetN/A

Short Float %0.1%

Short Ratio0.29

Dividend

		Industry Rank	Sector Rank
Dividend Yield	8.01%

Yearly Dividend2.67

Dividend Growth(5Y)3.39%

DP150%

Div Incr Years1

Div Non Decr Years10

Ex-Date06-13 2025-06-13 (0.2621)

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	22.77
Fwd PE	N/A
P/S	62.57
P/FCF	7.18
P/OCF	7.18
P/B	0.87
P/tB	0.87
EV/EBITDA	N/A

EPS(TTM)1.61

EY4.39%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)5.11

FCFY13.93%

OCF(TTM)5.11

OCFY13.93%

SpS0.59

BVpS42.24

TBVpS42.24

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	4.36%
ROE	4.4%
ROCE	0.17%
ROIC	0.13%
ROICexc	0.13%
ROICexgc	0.13%
OM	12.29%
PM (TTM)	317.04%
GM	100%
FCFM	871.86%

ROA(3y)1.06%

ROA(5y)5.33%

ROE(3y)1.07%

ROE(5y)5.44%

ROIC(3y)0.2%

ROIC(5y)0.12%

ROICexc(3y)0.2%

ROICexc(5y)0.12%

ROICexgc(3y)0.2%

ROICexgc(5y)0.12%

ROCE(3y)0.25%

ROCE(5y)0.16%

ROICexcg growth 3Y199.74%

ROICexcg growth 5Y4.01%

ROICexc growth 3Y199.74%

ROICexc growth 5Y4.01%

OM growth 3Y169.88%

OM growth 5Y-0.74%

PM growth 3Y-30.97%

PM growth 5Y-28.42%

GM growth 3YN/A

GM growth 5YN/A

F-Score8

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	250
Cash Conversion	N/A
Profit Quality	275%
Current Ratio	0.29
Quick Ratio	0.29
Altman-Z	67.46

F-Score8

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)12.59%

EPS 3Y-26.89%

EPS 5Y-24.8%

EPS Q2Q%-372.58%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-7.64%

Revenue growth 3Y5.76%

Revenue growth 5Y8.91%

Sales Q2Q%-10.82%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-53.5%

EBIT growth 3Y185.41%

EBIT growth 5Y8.1%

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y106.25%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y106.25%

OCF growth 3YN/A

OCF growth 5YN/A

BLACKROCK HEALTH SCIENCES (BME) Stock Price, Quote, News and Overview

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

5.2 History

5.3 Sustainability

More info and screens